Rani Therapeutics Holdings Stock Price Prediction
| RANI Stock | USD 1.39 0.04 2.96% |
Momentum 44
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.08) | EPS Estimate Current Year (0.44) | EPS Estimate Next Year (0.32) | Wall Street Target Price 9.25 | EPS Estimate Current Quarter (0.12) |
Using Rani Therapeutics hype-based prediction, you can estimate the value of Rani Therapeutics Holdings from the perspective of Rani Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Rani Therapeutics using Rani Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Rani using crowd psychology based on the activity and movement of Rani Therapeutics' stock price.
Rani Therapeutics Implied Volatility | 1.2 |
Rani Therapeutics' implied volatility exposes the market's sentiment of Rani Therapeutics Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Rani Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Rani Therapeutics stock will not fluctuate a lot when Rani Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Rani Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Rani because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Rani Therapeutics after-hype prediction price | USD 1.39 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Rani contract
Based on the Rule 16, the options market is currently suggesting that Rani Therapeutics Holdings will have an average daily up or down price movement of about 0.075% per day over the life of the 2026-04-17 option contract. With Rani Therapeutics trading at USD 1.39, that is roughly USD 0.001043 . If you think that the market is fully incorporating Rani Therapeutics' daily price movement you should consider acquiring Rani Therapeutics Holdings options at the current volatility level of 1.2%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Rani Therapeutics Basic Forecasting Models to cross-verify your projections. Rani Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Rani Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Rani Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Rani Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Rani Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Rani Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Rani Therapeutics' historical news coverage. Rani Therapeutics' after-hype downside and upside margins for the prediction period are 0.07 and 10.13, respectively. We have considered Rani Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Rani Therapeutics is abnormally volatile at this time. Analysis and calculation of next after-hype price of Rani Therapeutics is based on 3 months time horizon.
Rani Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Rani Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rani Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Rani Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.18 | 8.77 | 0.00 | 0.04 | 9 Events / Month | 5 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.39 | 1.39 | 0.00 |
|
Rani Therapeutics Hype Timeline
Rani Therapeutics is at this time traded for 1.39. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.04. Rani is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is at this time at -0.18%. %. The volatility of related hype on Rani Therapeutics is about 3623.97%, with the expected price after the next announcement by competition of 1.43. About 28.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.68. Rani Therapeutics recorded a loss per share of 0.77. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in about 9 days. Check out Rani Therapeutics Basic Forecasting Models to cross-verify your projections.Rani Therapeutics Related Hype Analysis
Having access to credible news sources related to Rani Therapeutics' direct competition is more important than ever and may enhance your ability to predict Rani Therapeutics' future price movements. Getting to know how Rani Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Rani Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IPHA | Innate Pharma | 0.00 | 8 per month | 0.00 | (0.05) | 4.02 | (5.21) | 39.49 | |
| MIST | Milestone Pharmaceuticals | (0.14) | 10 per month | 4.24 | 0 | 6.15 | (5.91) | 34.31 | |
| CRDF | Cardiff Oncology | 0.20 | 7 per month | 2.93 | 0.09 | 9.28 | (5.34) | 20.56 | |
| CYBN | Cybin Inc | 0.17 | 9 per month | 3.65 | 0.13 | 6.06 | (7.30) | 18.15 | |
| CRBP | Corbus Pharmaceuticals Holding | (0.07) | 26 per month | 0.00 | (0.23) | 4.60 | (8.37) | 32.00 | |
| APLT | Applied Therapeutics | 0.02 | 7 per month | 0.00 | (0.23) | 10.00 | (15.73) | 83.66 | |
| SGMO | Sangamo Therapeutics | (0.01) | 9 per month | 0.00 | (0.17) | 7.69 | (6.98) | 21.63 | |
| TNXP | Tonix Pharmaceuticals Holding | 1.75 | 8 per month | 4.11 | (0) | 6.92 | (6.56) | 22.54 | |
| ELTX | Elicio Therapeutics | 0.26 | 9 per month | 0.00 | (0.07) | 5.50 | (4.15) | 21.98 | |
| MOLN | Molecular Partners AG | 0.24 | 5 per month | 3.41 | 0.03 | 4.73 | (5.45) | 26.47 |
Rani Therapeutics Additional Predictive Modules
Most predictive techniques to examine Rani price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Rani using various technical indicators. When you analyze Rani charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Rani Therapeutics Predictive Indicators
The successful prediction of Rani Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Rani Therapeutics Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Rani Therapeutics based on analysis of Rani Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Rani Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Rani Therapeutics's related companies. | 2025 | 2026 (projected) | Interest Debt Per Share | 1.4 | 1.89 | Revenue Per Share | 0.0325 | 0.0504 |
Currently Active Assets on Macroaxis
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |